Stoke Therapeutics (NASDAQ:STOK) Insider Sells $60,517.54 in Stock

Key Points

• Insider sale: Jason Hoitt sold 1,931 shares on March 18 at an average price of $31.34 for $60,517.54 (after selling 1,781 shares on March 17), cutting his stake by 15.82% to 10,276 shares.
• STOK rallied about 7.0% to $33.19 on higher-than-average volume; the stock has a market cap near $1.96 billion, a 1‑year range of $5.35–$40.22, and 50/200-day moving averages around $32.61/$29.90.
• Analysts largely raised or reiterated bullish ratings and price targets (consensus ~$39.83) and cited pipeline upside for STK‑001, but the company also missed quarterly EPS and revenue expectations and granted inducement stock options that could add future dilution.

Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) insider Jason Hoitt sold 1,931 shares of the stock in a transaction dated Wednesday, March 18th. The stock was sold at an average price of $31.34, for a total value of $60,517.54. Following the transaction, the insider directly owned 10,276 shares in the company, valued at approximately $322,049.84. The trade was a 15.82% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Jason Hoitt also recently made the following trade(s):

• On Tuesday, March 17th, Jason Hoitt sold 1,781 shares of Stoke Therapeutics stock. The stock was sold at an average price of $33.01, for a total transaction of $58,790.81.

Stoke Therapeutics Trading Up 7.0%

STOK stock traded up $2.17 on Thursday, hitting $33.19. The company's stock had a trading volume of 853,428 shares, compared to its average volume of 754,489. The stock has a market cap of $1.96 billion, a price-to-earnings ratio of 49.54 and a beta of 1.07. Stoke Therapeutics, Inc. has a 1 year low of $5.35 and a 1 year high of $40.22. The firm has a 50 day moving average of $32.61 and a two-hundred day moving average of $29.90.

Stoke Therapeutics News Roundup

Here are the key news stories impacting Stoke Therapeutics this week:

• Positive Sentiment: Multiple analysts raised or reiterated bullish ratings and price targets this week (BTIG reaffirmed "buy" with a $39 target; Wedbush lifted its target to $38; Needham raised its target toward $40 and Chardan keeps a $35 target) — these actions increase buy-side interest and provide technical/supportive buying. Read More.
• Positive Sentiment: Pipeline story: coverage highlighting STK‑001’s potential to restore developmental deficits in Dravet syndrome (beyond seizure control) supports upside for long-term clinical value if trials continue to show benefit. Read More.
• Neutral Sentiment: Company granted inducement stock options to new hires — helps recruiting but adds potential future dilution; not an immediate earnings impact. Read More.
• Negative Sentiment: Quarterly results missed expectations: EPS of ($0.97) vs. consensus ($0.75) and revenue $1.4M vs. $5.3M expected — the earnings/revenue shortfall is the clearest near-term driver of prior downward pressure and investor concern about near-term commercialization/visibility. Read More.
• Negative Sentiment: Insider sale disclosed — Director Arthur A. Levin sold 605 shares (~$22k) in mid‑March; small in dollar terms but sometimes interpreted as a mild negative signal by short‑term traders. Read More.

Institutional Trading of Stoke Therapeutics

Large investors have recently modified their holdings of the company. Kestra Advisory Services LLC acquired a new position in Stoke Therapeutics in the fourth quarter worth approximately $26,000. Harbour Investments Inc. boosted its stake in shares of Stoke Therapeutics by 312.9% during the 4th quarter. Harbour Investments Inc. now owns 1,185 shares of the company's stock worth $38,000 after acquiring an additional 898 shares in the last quarter. Generali Investments Management Co LLC acquired a new position in shares of Stoke Therapeutics in the 3rd quarter worth $41,000. BNP Paribas Financial Markets raised its position in shares of Stoke Therapeutics by 66.2% during the second quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company's stock worth $48,000 after purchasing an additional 1,668 shares during the period. Finally, Tower Research Capital LLC TRC lifted its holdings in shares of Stoke Therapeutics by 461.0% during the second quarter. Tower Research Capital LLC TRC now owns 4,370 shares of the company's stock valued at $50,000 after purchasing an additional 3,591 shares during the last quarter.

Wall Street Analysts Forecast Growth

STOK has been the topic of several analyst reports. Needham & Company LLC increased their price target on Stoke Therapeutics from $35.00 to $40.00 and gave the stock a "buy" rating in a research note on Tuesday. Wolfe Research initiated coverage on Stoke Therapeutics in a report on Monday, February 23rd. They issued an "outperform" rating and a $40.00 price target for the company. Canaccord Genuity Group upped their price objective on shares of Stoke Therapeutics from $28.00 to $36.00 and gave the company a "buy" rating in a research note on Monday, January 5th. Weiss Ratings reiterated a "hold (c-)" rating on shares of Stoke Therapeutics in a report on Monday, December 29th. Finally, HC Wainwright boosted their target price on shares of Stoke Therapeutics from $35.00 to $50.00 and gave the company a "buy" rating in a report on Monday, December 15th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $39.83.

Stoke Therapeutics Company Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company's lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.